Market research
KUR.F Kura Oncology, Inc
F EUR Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 817M
- P/E ratio
- Not available
- Analyst target
- 44.57
- Dividend yield
- Not available
- Beta
- 0.47
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 817M
- P/E ratio
- Not available
- Analyst target
- 44.57
- Dividend yield
- Not available
- Beta
- 0.47
About
About Kura Oncology, Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Research context
Kura Oncology, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the KUR.F discussion.
5 years, 7 months ago
Kura Oncology, Inc is currently in a long term downtrend where the price is trading 33.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Kura Oncology, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 46.4% to $-26M since the same quarter in the previous year.
Finally, its free cash flow fell by 33.4% to $-19M since the same quarter in the previous year.
Based on the above factors, Kura Oncology, Inc gets an overall score of 1/5.